Advances in pharmacotherapy for tobacco dependence

Jonathan Foulds, Michael Burke, Michael Steinberg, Jill M. Williams, Douglas M. Ziedonis

Research output: Contribution to journalReview article

86 Citations (Scopus)

Abstract

The discovery that bupropion is an effective treatment for tobacco dependence has triggered a rapid increase in development of potential new non-nicotine pharmacotherapies, including bromocriptine, glucose, GTS-21, reboxetine, rimonabant, selegeline and varenicline. Successful new products will need to have excellent side-effect profiles in addition to proven efficacy. New faster delivery nicotine replacement products have the promise of addressing a broader list of indications, including treatment of nicotine withdrawal during temporary abstinence and long-term nicotine maintenance. Nicotine vaccines will need to demonstrate efficacy and also improve certain consumer acceptability characteristics (e.g., frequency of injections required) before they can become widely used and successful therapies. The best hope of improved treatment comes from combining existing and new pharmacotherapies with effective behavioural therapy.

Original languageEnglish (US)
Pages (from-to)39-53
Number of pages15
JournalExpert Opinion on Emerging Drugs
Volume9
Issue number1
DOIs
StatePublished - May 1 2004

Fingerprint

Tobacco Use Disorder
Drug Therapy
Nicotine
rimonabant
Tobacco Use Cessation Products
Therapeutics
Bupropion
Bromocriptine
Vaccines
Maintenance
Glucose
Injections

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Foulds, J., Burke, M., Steinberg, M., Williams, J. M., & Ziedonis, D. M. (2004). Advances in pharmacotherapy for tobacco dependence. Expert Opinion on Emerging Drugs, 9(1), 39-53. https://doi.org/10.1517/14728214.9.1.39
Foulds, Jonathan ; Burke, Michael ; Steinberg, Michael ; Williams, Jill M. ; Ziedonis, Douglas M. / Advances in pharmacotherapy for tobacco dependence. In: Expert Opinion on Emerging Drugs. 2004 ; Vol. 9, No. 1. pp. 39-53.
@article{e9edfc04381c44ba96ce31d4eb26adaf,
title = "Advances in pharmacotherapy for tobacco dependence",
abstract = "The discovery that bupropion is an effective treatment for tobacco dependence has triggered a rapid increase in development of potential new non-nicotine pharmacotherapies, including bromocriptine, glucose, GTS-21, reboxetine, rimonabant, selegeline and varenicline. Successful new products will need to have excellent side-effect profiles in addition to proven efficacy. New faster delivery nicotine replacement products have the promise of addressing a broader list of indications, including treatment of nicotine withdrawal during temporary abstinence and long-term nicotine maintenance. Nicotine vaccines will need to demonstrate efficacy and also improve certain consumer acceptability characteristics (e.g., frequency of injections required) before they can become widely used and successful therapies. The best hope of improved treatment comes from combining existing and new pharmacotherapies with effective behavioural therapy.",
author = "Jonathan Foulds and Michael Burke and Michael Steinberg and Williams, {Jill M.} and Ziedonis, {Douglas M.}",
year = "2004",
month = "5",
day = "1",
doi = "10.1517/14728214.9.1.39",
language = "English (US)",
volume = "9",
pages = "39--53",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "1",

}

Foulds, J, Burke, M, Steinberg, M, Williams, JM & Ziedonis, DM 2004, 'Advances in pharmacotherapy for tobacco dependence', Expert Opinion on Emerging Drugs, vol. 9, no. 1, pp. 39-53. https://doi.org/10.1517/14728214.9.1.39

Advances in pharmacotherapy for tobacco dependence. / Foulds, Jonathan; Burke, Michael; Steinberg, Michael; Williams, Jill M.; Ziedonis, Douglas M.

In: Expert Opinion on Emerging Drugs, Vol. 9, No. 1, 01.05.2004, p. 39-53.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Advances in pharmacotherapy for tobacco dependence

AU - Foulds, Jonathan

AU - Burke, Michael

AU - Steinberg, Michael

AU - Williams, Jill M.

AU - Ziedonis, Douglas M.

PY - 2004/5/1

Y1 - 2004/5/1

N2 - The discovery that bupropion is an effective treatment for tobacco dependence has triggered a rapid increase in development of potential new non-nicotine pharmacotherapies, including bromocriptine, glucose, GTS-21, reboxetine, rimonabant, selegeline and varenicline. Successful new products will need to have excellent side-effect profiles in addition to proven efficacy. New faster delivery nicotine replacement products have the promise of addressing a broader list of indications, including treatment of nicotine withdrawal during temporary abstinence and long-term nicotine maintenance. Nicotine vaccines will need to demonstrate efficacy and also improve certain consumer acceptability characteristics (e.g., frequency of injections required) before they can become widely used and successful therapies. The best hope of improved treatment comes from combining existing and new pharmacotherapies with effective behavioural therapy.

AB - The discovery that bupropion is an effective treatment for tobacco dependence has triggered a rapid increase in development of potential new non-nicotine pharmacotherapies, including bromocriptine, glucose, GTS-21, reboxetine, rimonabant, selegeline and varenicline. Successful new products will need to have excellent side-effect profiles in addition to proven efficacy. New faster delivery nicotine replacement products have the promise of addressing a broader list of indications, including treatment of nicotine withdrawal during temporary abstinence and long-term nicotine maintenance. Nicotine vaccines will need to demonstrate efficacy and also improve certain consumer acceptability characteristics (e.g., frequency of injections required) before they can become widely used and successful therapies. The best hope of improved treatment comes from combining existing and new pharmacotherapies with effective behavioural therapy.

UR - http://www.scopus.com/inward/record.url?scp=2642580863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2642580863&partnerID=8YFLogxK

U2 - 10.1517/14728214.9.1.39

DO - 10.1517/14728214.9.1.39

M3 - Review article

C2 - 15155135

AN - SCOPUS:2642580863

VL - 9

SP - 39

EP - 53

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 1

ER -